Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8506341 | 0.84 | HDAC4 (0.51) | HDAC4HSD11B1KDM4EGAAHTT | |
| SCHEMBL5007609 | 0.80 | HSD11B1 (0.53) | HDAC4HSD11B1KDM4EGAAHTT | |
| SCHEMBL4445340 | 0.80 | HSD11B1 (0.53) | HDAC4HSD11B1KDM4EGAAHTT | |
| SCHEMBL15778834 | 0.80 | SMN1; SMN2 (0.53) | HDAC4HSD11B1KDM4EGAAHTT | |
| SCHEMBL1975025 | 0.80 | HSD11B1 (0.56) | HDAC4HSD11B1KDM4EGAAHTT | |
| SCHEMBL1769917 | 0.79 | HSD11B1 (0.51) | HDAC4HSD11B1KDM4EGAAHTT | |
| SCHEMBL13545175 | 0.79 | HSD11B1 (0.51) | HDAC4HSD11B1KDM4EGAAHTT | |
| SCHEMBL7767870 | 0.76 | OPRM1 (0.54) | HDAC4HSD11B1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6499510 | 0.76 | HDAC4 (0.58) | HDAC4HSD11B1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2321735 | 0.75 | HSD11B1 (0.59) | HDAC4HSD11B1KDM4EGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3624805-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | Kapoor, Tarun, M. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213712-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | KAPOOR TARUN M (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | HDAC4 1557/4885HSD11B1 1670/4885KDM4E 3179/4885 |
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | HDAC4 1557/4885HSD11B1 1670/4885KDM4E 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.